Reitler’s Life Science practice group leverages decades of accomplishment representing companies across the spectrum of the industry lifecycle, from early stage biotech and generic drug companies to mature drug developers, in all manner of transactions.
We have advised Life Science companies and investors on in-licensing and out-licensing transactions, technology transfer transactions, public, private and PIPE financing transactions, innovative joint ventures, co-development and collaboration arrangement and mergers & acquisitions.
The Life Sciences environment is known for its ever shifting landscape, which is why our clients prize the practical legal advice we provide. With the unyielding pace of new scientific discoveries, our clients need to negotiate smartly and swiftly while continuing to realize their goals and achieve superior results. Our ability to identify with these needs, think creatively, and employ deep industry knowledge and connections are why clients see us as their ideal representatives.
Furthermore, as our representative transactions in Life Science demonstrate, we are comfortable providing advice in complex, milestone-driven out-licensing transactions for early stage biotech concerns as well as in the sale of later stage generic drug manufacturer to public acquirers. We come equipped with the wisdom, intellectual dexterity and flexibility needed to facilitate the execution of all manner of Life Science deals. This, combined with our strong corporate fundamentals and reinforcement from adjacent practice areas, make Reitler Kailas & Rosenblatt a wise choice for counsel in Life Science transactions.